OsteoporeASX:OSX +25.00% 3-Year ROIIC % is 134.50 as of Dec. 2025, which is 23% above its 10-year median of 109.09. The stock has 7 warning signs investors should review. Among 800 Medical Devices & Instruments companies, Osteopore ranks better than 91.25% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Osteopore's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 134.50%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Osteopore's 3-Year ROIIC % or its related term are showing as below:
ASX:OSX's 3-Year ROIIC % is ranked better than 91.25% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.455
vs ASX:OSX: 134.50
Osteopore (ASX:OSX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Osteopore 3-Year ROIIC % Related Terms
Osteopore 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Osteopore's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSX vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Osteopore's 3-Year ROIIC % falls into.
Osteopore's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.41 (Dec. 2025) - -4.482 (Dec. 2022) )
/
( 1.612 (Dec. 2025) - 0.815 (Dec. 2022) )
=
1.072
/
0.797
=
134.50%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Osteopore (ASX:OSX) has a 3-Year ROIIC % of 134.50 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Osteopore and its competitors. This is 23% above median its historical median of 109.09. According to the industry distribution chart, Osteopore ranks #70 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Osteopore's 3-Year ROIIC % too high?
Osteopore's current 3-Year ROIIC % of 134.50 is 23% above median its 10-year median of 109.09. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.46. Osteopore's value of 134.50 is 9144% above this industry median. Based on the distribution chart, Osteopore ranks #70 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Osteopore's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #70 out of 800 companies for 3-Year ROIIC %. This places Osteopore in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.46. Osteopore's value of 134.50 is 9144% above this benchmark. While the company's 10-year median is 109.09 vs. the industry median of 1.46, Osteopore has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.46, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Osteopore's current 3-Year ROIIC % of 134.50 is 9144% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Osteopore and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current 3-Year ROIIC % is 134.50, which is 23% above median its own 10-year median of 109.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 75% below its estimated fair value. The current 3-Year ROIIC % is 134.50, which is 23% above median its 10-year median of 109.09 and 9144% above the Medical Devices & Instruments industry median of 1.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current 3-Year ROIIC % is 134.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 